Most Clicked BIO SmartBrief Stories


1. Report: Biosimilar market to expand rapidly

BIO SmartBrief | Jul 02, 2015

The worldwide market for biosimilars could reach $55 billion by 2020 and biologics could replace as much as 70% of the chemical drug market in the next 20 years, according to a report from GBI Research. GBI pointed to 642 biosimilar trials underway, with more than half focused on oncology and immunotherapy treatments. BioSpectrum Asia (07/01)


2. Baxter announces Baxalta spinoff

BIO SmartBrief | Jul 02, 2015

Baxter BioScience, a division of Baxter International, has become an independent company named Baxalta, Baxter announced. Baxalta will concentrate on the development of rare disease treatments and intends to boost its portfolio of hematology and immune globulin drugs. It also will expand its cancer drug pipeline to accommodate patients who have limited treatment options. Genetic Engineering & Biotechnology News (07/01)


3. Celgene, Juno sign $1B collaboration deal

BIO SmartBrief | Jun 30, 2015

Celgene has entered into a 10-year, nearly $1 billion collaboration with Juno Therapeutics to research and develop treatments for cancer and autoimmune diseases, plus therapies targeting immune system cells. Under the terms of agreement, Juno will receive an upfront payment of $150 million plus an additional payment from Celgene for 9.1 million of its shares at $93 apiece. Celgene will get the option to increase its stake in Juno to up to 30%. Juno will develop and market drugs arising from the collaboration in North America, and Celgene will get the remaining worldwide rights. Bloomberg (06/30)


4. Bristol-Myers Squibb ceases antiviral discovery program

BIO SmartBrief | Jun 29, 2015

Bristol-Myers Squibb has decided to cancel a program that identifies new antiviral drug candidates, including its work on hepatitis B and HIV. The company said products that have reached market and candidates that have reached clinical development, such as the HIV attachment inhibitor BMS-663068 and hepatitis C drug daclatasvir, will not be affected. PharmaTimes (U.K.) (06/25) Reuters (06/25)


5. Judge rules against biotech crop ban in Maui County

BIO SmartBrief | Jul 01, 2015

U.S. District Court Chief Judge Susan Oki Mollway on Tuesday overturned Maui County's biotech crop ban, which prohibits the cultivation of the crops until studies are conducted to show they are safe and beneficial. The creation of the ban is not within the county's authority, Mollway said. The Huffington Post (06/30)


6. Novartis acquires biotech firm Spinifex

BIO SmartBrief | Jun 30, 2015

Novartis is buying the U.S.-Australian company Spinifex for $200 million, with additional payments linked to designated milestones. The acquisition will allow the Swiss drugmaker to continue clinical trials of the neuropathic pain medication EMA401, which had positive results in patients with post-herpetic neuralgia in midstage trials. Yahoo (06/29)


7. Drugs from Immunovaccine, Incyte to be combined in cancer trial

BIO SmartBrief | Jun 29, 2015

Immunovaccine will collaborate with Incyte in a Phase Ib trial to evaluate the combination of Immunovaccine's T cell-activating immunotherapy DPX-Survivac and Incyte's epacadostat as a treatment for platinum-sensitive ovarian cancer in patients who have an increased risk of disease recurrence. The firms will likely file an investigational new drug application for the study in the U.S. and Canada later this year. Pharmaceutical Business Review Online (06/26)


8. Juno's lymphoma drug application accepted by FDA

BIO SmartBrief | Jun 30, 2015

Juno Therapeutics' investigational new drug application for its immunotherapy JCAR017 as a treatment for non-Hodgkin lymphoma has been accepted by the FDA. An early-stage trial is planned for this year. American City Business Journals (06/29)


9. Seres pulls in $134M from IPO

BIO SmartBrief | Jun 29, 2015

Seres Therapeutics raised nearly $134 million from an initial public offering that sold 7.43 million shares. The Cambridge, Mass.-based firm is developing an oral treatment for Clostridium difficile. Xconomy (06/25)


10. AstraZeneca partners with Eolas on smoking cessation therapy in $145M deal

BIO SmartBrief | Jul 01, 2015

AstraZeneca has agreed to collaborate with Eolas Therapeutics on the development and commercialization of Eolas Orexin-1 Receptor Antagonist, a smoking cessation treatment, in a deal worth $145 million. Under the terms of the agreement, Eolas is entitled to receive an undisclosed upfront payment, milestone fees and sales royalties. BioSpace (San Francisco) (06/30)




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more